Jinwu Financial News | According to the Hong Kong Stock Exchange's disclosure on April 30, Mirxes Holding Company Limited (Mirxes Holding Company Limited) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC (CICC) and CCBI (CCBI) as co-sponsors. The company submitted a listing application to the Hong Kong Stock Exchange on July 25, 2023.
Established in 2014, the company is a microribonucleic acid (“miRNA”) technology company originating in Singapore, focusing on popularizing disease screening and diagnosis solutions around the world. It has one core product (i.e. GastroClear), two other commercial products (i.e. LungClear and Fortitude), and six pre-clinical candidate products.
On the financial side, the company earned 177.59 million yuan and 24.185 million US dollars from 2022 to 2023, corresponding losses due to shareholders of the company's equity shareholders of 56.6416 million and 69.225 million US dollars.
